Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: neurodegenerative disorders therapeutics - Samaritan/McGill University

Next Previous
X
Search
Drug Profile

Research programme: neurodegenerative disorders therapeutics - Samaritan/McGill University

Alternative Names: Caprospinol; SP-004; SP-008; SP-04; SP-04m; SP-08; SP-233

Latest Information Update: 16 Jul 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Georgetown University; McGill University; Samaritan Pharmaceuticals
  • Developer CHDI; McGill University; Samaritan Pharmaceuticals
  • Class Caproates; Piperazines; Small molecules; Spirostans; Steroids
  • Mechanism of Action Acetylcholinesterase inhibitors; Amyloid beta-protein inhibitors; Sigma-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Alzheimer's disease; Huntington's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in Canada (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Huntington's-disease in USA (PO)
  • 24 Jan 2008 The CHDI Foundation has non-exclusively licensed six compounds, including caprospinol, Sp 04, Sp 04m and Sp 08, for evaluation as potential therapeutics for Huntington's disease

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top